Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01336634
Title Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult
Covered Countries USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU

Facility Status City State Zip Country Details
Novartis Investigative Site Los Angeles California 90033 United States Details
Novartis Investigative Site Orange California 92868 United States Details
Novartis Investigative Site Aurora Colorado 80045 United States Details
Novartis Investigative Site Tampa Florida 33612 United States Details
Novartis Investigative Site Baltimore Maryland 21231 United States Details
Novartis Investigative Site Boston Massachusetts 02114 United States Details
Novartis Investigative Site Boston Massachusetts 02215 United States Details
Novartis Investigative Site Ann Arbor Michigan 48109-5848 United States Details
Novartis Investigative Site Saint Louis Missouri 63110 United States Details
Novartis Investigative Site Lebanon New Hampshire 03756 United States Details
Novartis Investigative Site New York New York 10065 United States Details
Novartis Investigative Site Columbus Ohio 43210 United States Details
Novartis Investigative Site Pittsburgh Pennsylvania 15232 United States Details
Novartis Investigative Site Seattle Washington 98109 United States Details
Novartis Investigative Site Madison Wisconsin 53792 United States Details
Novartis Investigative Site Caen Cedex 9 14033 France Details
Novartis Investigative Site Lille Cedex 59037 France Details
Novartis Investigative Site Marseille Cedex 20 13915 France Details
Novartis Investigative Site Pierre Benite 69495 France Details
Novartis Investigative Site Saint-Herblain Cedex 44805 France Details
Novartis Investigative Site Strasbourg Cedex 67091 France Details
Novartis Investigative Site Toulouse Cedex 9 31059 France Details
Novartis Investigative Site Villejuif 94805 France Details
Novartis Investigative Site Frankfurt/Main 60487 Germany Details
Novartis Investigative Site Grosshansdorf 22927 Germany Details
Novartis Investigative Site Heidelberg 69126 Germany Details
Novartis Investigative Site Moers 47441 Germany Details
Novartis Investigative Site Milano 20133 Italy Details
Novartis Investigative Site Milano 20141 Italy Details
Novartis Investigative Site Orbassano 10043 Italy Details
Novartis Investigative Site Osaka 534-0021 Japan Details
Novartis Investigative Site Tokyo 104-0045 Japan Details
Novartis Investigative Site Seoul 110-744 Korea, Republic of Details
Novartis Investigative Site Seoul 120-752 Korea, Republic of Details
Novartis Investigative Site Seoul 135-710 Korea, Republic of Details
Novartis Investigative Site Amsterdam 1081 Netherlands Details
Novartis Investigative Site Groningen 9713 Netherlands Details
Novartis Investigative Site Oslo 0310 Norway Details
Novartis Investigative Site Barcelona 08025 Spain Details
Novartis Investigative Site Barcelona 08036 Spain Details
Novartis Investigative Site Madrid 28006 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Malaga 29010 Spain Details
Novartis Investigative Site Pamplona 31008 Spain Details
Novartis Investigative Site Sevilla 41013 Spain Details
Novartis Investigative Site Taichung 40705 Taiwan Details
Novartis Investigative Site Taipei Taiwan Details
Novartis Investigative Site London SW3 6JJ United Kingdom Details
Novartis Investigative Site Oxford OX3 7LJ United Kingdom Details
Novartis Investigative Site Sutton SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field